A randomised controlled trial evaluated the glucose-lowering efficacy of empagliflozin, an SGLT2 inhibitor, as an adjunctive treatment in patients with HNF1A-related maturity-onset diabetes of the young (HNF1A-MODY), a rare monogenic form of diabetes. Over a 4-week intervention period, patients receiving empagliflozin alongside existing glucose-lowering therapies demonstrated significantly improved glycemic control measured by continuous glucose monitoring compared to placebo. Key secondary endpoints included reductions in 24-hour urinary glucose excretion, elevated estimated renal glucose thresholds, and lower fasting plasma glucose levels, with no substantial increase in hypoglycemic episodes or adverse events reported. The findings support empagliflozin's clinical relevance as a second-line or third-line therapeutic option even in HNF1A-MODY patients, despite the condition's potentially reduced SGLT2 expression, establishing evidence for SGLT2 inhibitor use in this specific genetic diabetes subtype.⁴

^Reference:

4. Maagensen H, Høyerup SO, Jensen JS, et al. Empagliflozin in HNF1A-MODY (MODY3)-a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care. 2026:dc252572.